| Basics |
Pacira BioSciences, Inc.
Pacira Pharmaceuticals Inc is a specialty and generic drug manufacturing company. The company develops, manufactures, and commercializes pharmaceutical products for use in hospitals and ambulatory surgery centers across the United States.
|
| IPO Date: |
February 3, 2011 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$1.03B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.86 | 2.08%
|
| Avg Daily Range (30 D): |
$0.43 | 1.92%
|
| Avg Daily Range (90 D): |
$0.42 | 1.76%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
.54M |
| Avg Daily Volume (90 D): |
.53M |
| Trade Size |
| Avg Trade Size (Sh.): |
84 |
| Avg Trade Size (Sh.) (30 D): |
50 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Inst.Trades: |
8,818 |
| Avg Inst. Trade: |
$1.77M |
| Avg Inst. Trade (30 D): |
$1.83M |
| Avg Inst. Trade (90 D): |
$1.83M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.33M |
| Avg Closing Trade (30 D): |
$2.42M |
| Avg Closing Trade (90 D): |
$2.53M |
| Avg Closing Volume: |
60.2K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.12
|
$-.11
|
|
Diluted EPS
|
|
$.12
|
$-.11
|
|
Revenue
|
$
|
$ 179.52M
|
$ 181.1M
|
|
Gross Profit
|
$
|
$ 145.24M
|
$ 140.23M
|
|
Net Income / Loss
|
$
|
$ 5.43M
|
$ -4.85M
|
|
Operating Income / Loss
|
$
|
$ 6.36M
|
$ 8.5M
|
|
Cost of Revenue
|
$
|
$ 34.28M
|
$ 40.87M
|
|
Net Cash Flow
|
$
|
$ -152.9M
|
$ 16.87M
|
|
PE Ratio
|
|
|
|
|
|
|
